share_log

Needham Reiterates Buy on BioCryst Pharma, Lowers Price Target to $12

Needham Reiterates Buy on BioCryst Pharma, Lowers Price Target to $12

Needham 重申買入 BioCryst Pharma,將目標股價下調至 12 美元
Benzinga ·  2023/08/03 13:27

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the price target from $14 to $12.

Needham分析師塞爾吉·貝蘭格重申了BioCryst Pharma(納斯達克股票代碼:BCRX)的買入,並將目標股價從14美元下調至12美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論